Table 7.
Scenario analyses of PHiD-CV 2+1 versus no vaccination or PCV13 2+1 vaccination programs in Malaysia
| Parameter | Base case | Scenario analysis | PHiD-CV versus no vaccination (ICER) | PHiD-CV versus PCV13 (cost saving [USD million]/QALYs gained) |
|---|---|---|---|---|
| Base case | – | – | 28,497a | 5.2/116 |
| Discount rate | 3% | 0% | 23,792a | 5.7/125 |
| Discount rate | 3% | 5% | 31,793 | 4.9/110 |
| AOM cases due to NTHi | 32.3% | 20.0% | 30,843a | 3.1/60 |
| Adjustment factor for total AOM cases | 1.0 | 0.7 | 31,371 | 5.2/75 |
| Adjustment factor for total AOM cases | 1.0 | 1.3 | 26,105a | 5.2/157 |
| Time horizon | 10 years | 100 years | 10,317b | 5.2/50 |
| Indirect effects | Excluded | Included | 21,032a | 5.2/116 |
AOM acute otitis media, ICER incremental cost-effectiveness ratio, NTHi non-typeable H. influenzae, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV pneumococcal polysaccharide and NTHi protein D conjugate vaccine, QALY quality-adjusted life-year, USD United States dollars
aCost-effective (<USD 30,999)
bHighly cost-effective (<USD 10,333)